Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1591965 | 0.98 | KMT2A (0.63) | KMT2AALDH1A1CYP1A2MEN1CYP3A4 | |
| Hydrochloric Acid SCHEMBL2543304 | 0.96 | KMT2A (0.61) | KMT2AALDH1A1CYP1A2MEN1CYP3A4 | |
| Nitric Acid SCHEMBL7231544 | 0.88 | KMT2A (0.53) | KMT2AALDH1A1CYP1A2MEN1CYP3A4 | |
| Nitric Acid SCHEMBL2075832 | 0.88 | KMT2A (0.53) | KMT2AALDH1A1CYP1A2MEN1CYP3A4 | |
| SCHEMBL2003357 | 0.81 | KMT2A (0.42) | KMT2AALDH1A1CYP1A2MEN1SIGMAR1 | |
| SCHEMBL3277604 | 0.80 | HSD17B1 (0.59) | KMT2ACYP1A2MEN1CYP3A4HDAC6 | |
| SCHEMBL3185695 | 0.79 | KMT2A (0.66) | KMT2AALDH1A1CYP1A2MEN1CYP3A4 | |
| SCHEMBL27704346 | 0.79 | KMT2A (0.55) | KMT2AALDH1A1CYP1A2MEN1CYP3A4 | |
| SCHEMBL1884582 | 0.79 | KMT2A (1.00) | KMT2AALDH1A1CYP1A2MEN1CYP3A4 | |
| SCHEMBL7874967 | 0.79 | ALDH1A1 (0.66) | KMT2AALDH1A1CYP1A2MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3976787-A | VASOCONSTRICTION | ARMOUR PHARMACEUTICAL COMPANY (US) | 1976-08-24 | — | — | US | claimed |
| CN-103524442-A | Pyrimidine compound, triazine compound and application thereof as medicine | LE SUN PHARMACEUTICALS LTD | 2014-01-22 | — | — | CN | disclosed |
| CN-102143953-B | Pyrimidines, triazines and their use as pharmaceutical agents | LE SUN PHARMACEUTICALS LTD | 2013-12-25 | — | — | CN | disclosed |
| US-8288400-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288400-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288400-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-8017619-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| EP-1692140-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-08-23 | — | — | EP | disclosed |
| US-7084159-B2 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-08-01 | — | — | US | disclosed |
| US-20050148603-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-07-07 | — | — | US | disclosed |
| WO-2005037843-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-1389206-A2 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20040023963-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | CAO JINGRONG (US) | 2004-02-05 | — | — | US | disclosed |
| US-6642227-B2 | Such as 2-methylsulfanyl-5-(2-phenylamino-pyrimidin-4-yl)-4-p-tolyl-thiophene-3 -carbonitrile; antiproliferative agents; stents | VERTEX PHARMACEUTICALS INCORPORATED | 2003-11-04 | — | — | US | disclosed |
| US-20030096816-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | disclosed |
| WO-2002083667-A2 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-10-24 | — | — | WO | disclosed |
| US-3976787-A | VASOCONSTRICTION | ARMOUR PHARMACEUTICAL COMPANY (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023963-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | LCK, MAPK1, MAP3K1 | KMT2A 3261/4885ALDH1A1 4198/4885CYP1A2 4005/4885 |
| US-20050148603-A1 | Compositions useful as inhibitors of protein kinases | MAP3K20, MAP3K1, MAP3K6 | KMT2A 2061/4885ALDH1A1 4728/4885CYP1A2 4630/4885 |
| US-20030096816-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | LCK, MAPK1, MAP3K1 | KMT2A 3261/4885ALDH1A1 4198/4885CYP1A2 4005/4885 |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K6 | KMT2A 2061/4885ALDH1A1 4728/4885CYP1A2 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.